Company profile: OM Pharma
1.1 - Company Overview
Company description
- Provider of microbial-derived immunotherapeutic products addressing acute and chronic immunological disorders from infections and inflammation, operating worldwide through partners and investing in R&D. Products include Broncho-Vaxom to regulate the immune system and prevent recurrent respiratory infections, Uro-Vaxom to treat and prevent recurrent lower urinary tract infections, and Dicynone for capillary hemorrhage prevention and treatment.
Products and services
- Broncho-Vaxom: A microbial-derived product employing lyophilized bacterial extracts to regulate the immune system and prevent recurrent respiratory infections
- Dicynone: A pharmacological medication indicated for prevention and treatment of capillary hemorrhages of various origins, including heavy menstrual bleeding and surgery
- Uro-Vaxom: A multi-strain extract of Escherichia coli that stimulates the immune system to treat and prevent recurrent lower urinary tract infections
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OM Pharma
Clever Culture Systems
HQ: Switzerland
Website
- Description: Provider of intelligent image analysis solutions using artificial intelligence, including APAS Independence for automated microbial environmental monitoring with digital records, audit trails, standardized workflows and reduced human error, and MRSA and VRE Analysis Modules that automate detection on chromogenic media for efficient infection control by reporting negatives and triaging positives for review.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clever Culture Systems company profile →
Fluoresentric
HQ: United States
Website
- Description: Provider of assay design, optimization, and custom manufacturing services for the healthcare and biotechnology sector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluoresentric company profile →
Genticel
HQ: France
Website
- Description: Provider of therapeutic vaccines and innovative immunotherapies to treat virus infections and virus-induced diseases, with an initial focus on HPV and HPV-induced conditions, including prevention of cervical cancer in HPV-infected women.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genticel company profile →
IncellDx
HQ: United States
Website
- Description: Provider of molecular diagnostics focused on detecting and monitoring life-threatening viral diseases, offering HPV OncoTect 3Dx assay quantifying E6/E7 mRNA for cervical cancer; incellKINE Long COVID in vitro diagnostic (CE marked); HPV E6/E7 mRNA probe; CMV mRNA probe (RUO); hybridization core reagents; and HPV control cells (RUO).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IncellDx company profile →
NanoView Biosciences
HQ: United States
Website
- Description: Provider of proprietary products supporting research, translation and delivery of precision medicine, built on a novel platform that uniquely identifies and characterizes exosomes. Offers high-throughput, cost-effective analysis, including Leprechaun for lentivirus and exosome biophysical characterization, contaminant detection, and concentration measurement using fluorescence and antibody-based methods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoView Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OM Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OM Pharma
2.2 - Growth funds investing in similar companies to OM Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OM Pharma
4.2 - Public trading comparable groups for OM Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →